NAD+, Quercetin, and Resveratrol: What the Clinical Research Actually Shows
Evidence Review | Updated December 2024 | 12 min read
The longevity supplement market is filled with bold claims, but what does the actual clinical research say? In this comprehensive review, we examine the peer-reviewed evidence for NAD+ supplementation and two compounds identified as sirtuin activators: quercetin and resveratrol. We'll look at what human clinical trials have demonstrated, where the evidence is strong, and where more research is needed.
The Core Concept: NAD+ and Sirtuins
Sirtuins are a family of NAD+-dependent enzymes linked to longevity, metabolism, and DNA repair. They require NAD+ as a co-substrate to function. As NAD+ levels decline with age, sirtuin activity may be compromised. The rationale behind combining NAD+ with sirtuin activators like quercetin and resveratrol is to provide both the "fuel" (NAD+) and the "accelerators" (compounds that enhance sirtuin activity).
NAD+: The Cellular Energy Currency
Nicotinamide adenine dinucleotide (NAD+) is a coenzyme found in all living cells. It plays essential roles in energy metabolism, serving as an electron carrier in reactions that convert nutrients to ATP. Beyond energy production, NAD+ is consumed by important enzyme families including sirtuins (involved in gene regulation and longevity pathways) and PARPs (involved in DNA repair).
The Age-Related Decline
Multiple studies have documented that NAD+ levels decrease with age. A 2021 review in Nature Reviews Molecular Cell Biology noted that age-related NAD+ decline has been observed in human liver, skin, brain, plasma, skeletal muscle, and immune cells. By middle age, NAD+ levels may fall to roughly half of youthful levels.
An 80-participant, multicenter, randomized, double-blind, placebo-controlled clinical trial examined NAD+ precursor supplementation over 60 days. Participants receiving 300, 600, or 900mg daily showed statistically significant increases in blood NAD+ at day 30 and day 60 compared to both placebo and baseline (all p≤0.001). The 600mg dose achieved the highest NAD+ concentrations.
Importantly, biological age markers (measured via Aging.Ai 3.0 calculator) stayed unchanged in treated groups while significantly increasing in the placebo group at day 60 (p<0.05). Supplementation was safe and well-tolerated with no adverse effects.
Yi L, et al. GeroScience. 2023;45(1):29-43. PMID: 36482258
In the first randomized, double-blind, placebo-controlled crossover trial of NAD+ precursor supplementation in healthy adults aged 55-79 years, 24 participants received 1000mg daily for 6 weeks. Supplementation was safe, well-tolerated, and increased NAD+ levels in peripheral blood mononuclear cells by approximately 2-fold. The study also noted a mild reduction in blood pressure and aortic stiffness in treated subjects.
Martens CR, et al. Nat Commun. 2018;9(1):1286. PMID: 29599478
Why NAD+ Matters for Sirtuins
Sirtuins cannot function without NAD+. Each time a sirtuin deacetylates a protein (one of its key functions), it consumes one molecule of NAD+. As NAD+ levels decline with age, sirtuin activity is compromised. This creates a rationale for both restoring NAD+ levels and enhancing sirtuin efficiency through activating compounds.
Quercetin: Senolytic and SIRT1 Activator
Quercetin is a flavonoid found in onions, apples, berries, and other plant foods. It was identified in the landmark 2003 study that discovered resveratrol as a sirtuin activator. Beyond its effects on sirtuins, quercetin has gained attention for its senolytic properties (ability to clear senescent cells) and its role as a CD38 inhibitor (CD38 is an enzyme that depletes NAD+ stores).
A systematic review and meta-analysis published in the Journal of the American Heart Association analyzed 7 randomized controlled trials comprising 587 patients. The results showed quercetin supplementation significantly reduced systolic blood pressure by 3.04 mmHg (p=0.028) and diastolic blood pressure by 2.63 mmHg (p<0.001). Effects were greater at doses exceeding 500mg/day.
Serban MC, et al. J Am Heart Assoc. 2016;5(7):e002713. PMID: 27405810
A more recent 2022 meta-analysis of 10 trials (841 participants) confirmed quercetin supplementation significantly decreased systolic blood pressure by 2.38 mmHg (p=0.01) in mixed populations. In normotensive subjects specifically, the reduction was 1.82 mmHg (p<0.0001). In pre-hypertensive and hypertensive subgroups, diastolic blood pressure was reduced by 3.14 mmHg (p<0.00001).
Results from 2022 meta-analysis of randomized controlled trials
In the first clinical trial directly demonstrating senolytics decrease senescent cells in humans, 9 subjects with diabetic kidney disease received dasatinib (100mg) plus quercetin (1000mg) for 3 days. Despite the drugs having elimination half-lives of less than 11 hours, this "hit-and-run" treatment significantly decreased senescent cell burden in adipose tissue, measured by reduced p16INK4A+ and p21CIP1+ cells and decreased senescence-associated secretory phenotype (SASP) factors.
Hickson LJ, et al. EBioMedicine. 2019;47:446-456. PMID: 31542391
Quercetin's Triple Action on the NAD+/SIRT1 Axis
Research has identified three mechanisms by which quercetin may support the NAD+/SIRT1 longevity pathway: (1) It activates SIRT1 directly, similar to resveratrol; (2) It inhibits CD38, an enzyme that depletes cellular NAD+ stores; (3) It can oxidize NADH and decrease the NADH/NAD+ ratio, potentially increasing available NAD+ for sirtuin activity.
Resveratrol: The Original Sirtuin Activator
Resveratrol, found in red wine and grape skins, was the most potent compound identified in the 2003 search for caloric restriction mimetics. It was shown to lower the binding affinity of SIRT1 for its substrate, increasing enzymatic activity up to 10-fold in laboratory studies. While translation to human clinical benefits has been more modest than preclinical results suggested, several meta-analyses have demonstrated measurable effects.
A systematic review and meta-analysis of 17 randomized controlled trials (21 treatment arms) found resveratrol supplementation significantly improved flow-mediated dilation (FMD) by 1.43% (95% CI: 0.98-1.88, p<0.001). FMD is a validated measure of endothelial function and vascular health. The analysis also found significant reductions in ICAM-1, a marker of vascular inflammation.
Mohammadipoor N, et al. Phytother Res. 2022;36(9):3526-3544. PMID: 35833325
A randomized trial allocated 48 healthy adults aged 55-65 years to either resveratrol supplementation or caloric restriction for 30 days. Both interventions significantly increased circulating SIRT1 (p<0.001). Resveratrol also significantly reduced plasma noradrenaline (p=0.037), indicating reduced sympathetic nervous system activity. The study confirmed that resveratrol mimics some effects of caloric restriction in healthy adults.
Pinheiro LC, et al. Nutrients. 2023;15(13):2949. PMID: 37447275
A systematic review and meta-analysis examining resveratrol in coronary artery disease found a significant reduction in TNF-alpha expression (p=0.0005) in primary prevention studies, with a dose-dependent relationship. Meta-regression identified associations between age, hypertension status, and lower doses with the extent of TNF-alpha alterations. High certainty of evidence supported the TNF-alpha reduction finding.
Damay VP, et al. Curr Vasc Pharmacol. 2024. PMID: 38958883
Analysis of 6 randomized controlled trials in cardiovascular disease patients found resveratrol significantly decreased CRP (p=0.01) and TNF-alpha (p=0.02), though IL-6 was not significantly affected. Cluster analysis of 27 studies suggested that lower doses (~270mg/day) over longer periods (~175 days) achieved the highest HDL increases, while higher doses (~450mg/day) over shorter periods (~74 days) produced greater triglyceride and blood pressure reductions.
Santana TM, et al. Complement Ther Clin Pract. 2022;46:101491. PMID: 34731768
The Synergy Hypothesis: Combining NAD+ with Activators
How These Compounds May Work Together
⛽
NAD+: The Fuel
Provides the essential co-substrate that sirtuins consume during each enzymatic reaction. Without adequate NAD+, sirtuin activity is limited.
🛡️
Quercetin: The Protector
Inhibits CD38 enzyme that depletes NAD+ stores while simultaneously activating SIRT1, offering dual support for the longevity pathway.
🚀
Resveratrol: The Accelerator
Lowers SIRT1's binding affinity for substrates, increasing enzymatic efficiency. May enhance the benefit derived from available NAD+.
A 2023 review in Nutrients explored the concept of synergistic NAD+ supplementation, noting that quercetin "can potently initiate SIRT1's intermediary action" and acts as "a potent CD38 inhibitor to maintain the integrity of NAD+ stores." The authors suggested that combining NAD+ precursors with compounds like quercetin and fisetin may "amplify NAD+-boosting effects" through complementary mechanisms.
Evidence Quality Summary
| Compound |
Dosage |
Key Findings |
Evidence Level |
| NAD+ |
500mg |
Significant NAD+ level increases; biological age markers stabilized vs placebo; safe and well-tolerated |
Strong (Multiple RCTs) |
| Quercetin |
250mg |
Blood pressure reduction (3mmHg systolic); senescent cell clearance in pilot trial; CD38 inhibition |
Strong (Meta-analyses) |
| Resveratrol |
150mg (98%) |
Improved endothelial function; increased circulating SIRT1; reduced inflammatory markers (TNF-alpha, CRP) |
Strong (Meta-analyses) |
What to Realistically Expect
NAD+ Level Changes
Clinical trials show measurable increases in blood NAD+ levels within 2-4 weeks of consistent supplementation. Subjective effects vary considerably between individuals.
Cardiovascular Markers
Meta-analyses of quercetin and resveratrol show blood pressure and endothelial function improvements typically manifest within 4-8 weeks of consistent use.
Inflammatory Markers
Reductions in inflammatory biomarkers like CRP and TNF-alpha have been observed in studies ranging from 8-12 weeks. These are typically measured via blood tests, not subjective feeling.
Long-Term Cellular Support
The premise of NAD+/sirtuin support is maintaining cellular function over time. Longevity-related outcomes require years to decades to assess and are not yet proven in human trials.
Important Limitations
While preclinical research on NAD+ and sirtuin activators is extensive, a 2025 Nature Metabolism review noted that "human clinical trials have shown limited efficacy" on hard clinical endpoints compared to the dramatic effects seen in animal models. The translation from rodent studies to human benefits is not straightforward. This formula supports cellular processes; it is not a treatment for any disease.
The Bottom Line
The combination of NAD+ with quercetin and resveratrol is supported by a coherent scientific rationale centered on the NAD+/SIRT1 longevity axis. Each compound has demonstrated measurable effects in human clinical trials: NAD+ precursors reliably increase blood NAD+ levels; quercetin reduces blood pressure and can clear senescent cells; resveratrol improves endothelial function and reduces inflammatory markers.
What remains less certain is whether these measurable biomarker changes translate to meaningful improvements in healthspan or longevity. The preclinical promise of NAD+ supplementation has not yet been fully validated in long-term human outcome studies. For those interested in supporting their cellular health based on current evidence, this combination represents one of the more scientifically grounded approaches available, while acknowledging that the field is still evolving.
References
1. Yi L, et al. The efficacy and safety of β-nicotinamide mononucleotide (NMN) supplementation in healthy middle-aged adults: a randomized, multicenter, double-blind, placebo-controlled, parallel-group, dose-dependent clinical trial. GeroScience. 2023;45(1):29-43. PMID: 36482258
2. Covarrubias AJ, et al. NAD+ metabolism and its roles in cellular processes during ageing. Nat Rev Mol Cell Biol. 2021;22(2):119-141. PMID: 33353981
3. Martens CR, et al. Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD+ in healthy middle-aged and older adults. Nat Commun. 2018;9(1):1286. PMID: 29599478
4. Serban MC, et al. Effects of Quercetin on Blood Pressure: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. J Am Heart Assoc. 2016;5(7):e002713. PMID: 27405810
5. Hickson LJ, et al. Senolytics decrease senescent cells in humans: Preliminary report from a clinical trial of Dasatinib plus Quercetin in individuals with diabetic kidney disease. EBioMedicine. 2019;47:446-456. PMID: 31542391
6. Mohammadipoor N, et al. Resveratrol supplementation efficiently improves endothelial health: A systematic review and meta-analysis of randomized controlled trials. Phytother Res. 2022;36(9):3526-3544. PMID: 35833325
7. Pinheiro LC, et al. Sirtuin 1 and Vascular Function in Healthy Women and Men: A Randomized Clinical Trial Comparing the Effects of Energy Restriction and Resveratrol. Nutrients. 2023;15(13):2949. PMID: 37447275
8. Damay VP, et al. Resveratrol as an Anti-inflammatory Agent in Coronary Artery Disease: A Systematic Review, Meta-Analysis and Meta-Regression. Curr Vasc Pharmacol. 2024. PMID: 38958883
9. Bonkowski MS, Sinclair DA. Slowing ageing by design: the rise of NAD+ and sirtuin-activating compounds. Nat Rev Mol Cell Biol. 2016;17(11):679-690. PMID: 27552971
10. Howitz KT, et al. Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan. Nature. 2003;425(6954):191-196. PMID: 12939617
11. Sharma A, et al. Potential Synergistic Supplementation of NAD+ Promoting Compounds as a Strategy for Increasing Healthspan. Nutrients. 2023;15(2):445. PMID: 36678323
12. Nature Metabolism. NAD+ precursor supplementation in human ageing: clinical evidence and challenges. 2025. PMID: 41083806
